MedTrace Logo

BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer

NCT01441297 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-08-25

No results posted yet for this study

Summary

Although chemotherapy is the primary treatment option for small cell lung cancer (SCLC), longterm survival is rare. SCLC is initially chemosensitive, but rapidly relapses in a chemoresistant form with an overall survival of \<5%. Consequently, novel therapies are urgently required and will likely arise from an improved understanding of the disease biology. Some preclinical studies have showed that fibroblast growth factor-2 induces proliferation and

Conditions

Interventions

DRUG

BIBF 1120

BIBF 1120 200mg bid, PO, daily until PD

Sponsors & Collaborators

  • National Cancer Center, Korea

    collaborator OTHER_GOV

  • Ji-youn Han

    lead OTHER_GOV

Principal Investigators

  • Ji-Youn Han, PhD. · National Cancer Center, Korea

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2015-10-31
Completion
2016-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441297 on ClinicalTrials.gov